Company intelligence / Profile preview
Ascentage Pharma
Suzhou, Jiangsu, Chinaascentage.com ↗
- Ownership
- Public · AAPG
- Employees
- ~567
- Development stage
- Other
01
Overview
Ascentage Pharma has one approved product, olverembatinib, for the treatment of drug-resistant chronic myeloid leukemia (CML) in China. The company is also advancing lisaftoclax (APG-2575), which has received Priority Review designation from China CDE. The company reported full-year 2024 unaudited financial results showing significant revenue growth.
- Therapeutic areas
- OtherOncologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $1.4B
- Total revenue
- $83.7M
- Enterprise value
- $1.4B
Beyond the preview
Go deeper on Ascentage Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ascentage Pharma.